FLGR-242 / Follistatin: Everything You Need To Know Before You Buy

There's a modified follistatin product called FLGR242 that's getting a lot of attention right now, and the claim attached to it is up to a pound and a half of skeletal muscle per week, which would put it well beyond anything a pharmaceutical company has managed to produce in a controlled trial.

The pathway it targets is real, backed by human genetics and decades of published work. The molecule itself has never been tested in a human clinical trial, and the person making the largest claims about it co-owns the company that manufactures and sells it.

None of this is medical advice, and I always recommend you consult with a licensed physician before putting anything into your body.

Start with the pathway, because if you don't understand it, nothing about the compound will make sense.

Your body produces a protein called myostatin, which acts as a brake on muscle growth. It circulates in your blood and binds to a receptor called ActRIIB sitting on the surface of your muscle cells.

And when that signal gets through, it activates a pathway called SMOD 2-3 that suppresses your body's ability to build muscle protein.

Follistatin is your body's own release for that brake. It binds to myostatin in circulation and pulls it out before it can ever reach the receptor, so the suppression signal never lands and the muscle cell is free to build.

That's the entire chain in sequence, myostatin binds the receptor, the receptor turns on the suppression pathway, and follistatin intercepts myostatin before any of it happens.

The reason people take this pathway seriously is that we already know what happens when the brake is missing. There was a case published in the New England Journal of Medicine back in 2004 where a child was born with a genetic mutation that knocked out his myostatin completely, and he was extraordinarily muscular from birth with completely normal organ development.

A large genetic study published in 2026 confirmed that people carrying these types of mutations consistently have more muscle mass, more strength, and less body fat than the general population.

Then there's the gene therapy work out of Nationwide Children's Hospital, where Mendell and colleagues injected a virus carrying the follistatin gene directly into the thigh muscles of patients with Becker muscular dystrophy and sporadic inclusion body myositis. In the 2017 Molecular Therapy paper, those patients didn't just show bigger muscle fibers on biopsy, they walked further on a six minute walk test.

In primates, the same approach produced muscles that were 15% larger and 78% stronger, and those results held through 15 months of follow-up.

The biology behind this pathway isn't really in dispute anymore, so the real question is whether FLGR242 specifically can deliver on what people are claiming for it.

FLGR242 is a modified version of follistatin 344 with two changes from the natural protein.

The first is called the FSII variant, and it comes from published peer reviewed work. The researchers removed the part of follistatin that binds to a protein called activen while keeping the part that binds to myostatin, which cut activin binding by roughly 250-fold.

That's marketed as a safety feature, because activin regulates a lot of tissue beyond muscle, including reproductive function and inflammation, and blocking it broadly causes problems.

Regeneron just ran a 999-patient Phase II trial called COURAGE where they tested myostatin blockade alone versus myostatin plus activen blockade together, and the results were striking.

Adding activen blockade on top of myostatin blockade nearly doubled the amount of lean mass that patients preserved and added 34% more fat loss.

So the piece that FLGR242 deliberately removed is roughly half of what makes this pathway work in a human body.

That same combination arm also had a 28.3% discontinuation rate and more severe side effects, so stripping out activin binding genuinely lowers risk. It lowers the effect size at the same time, and that trade is worth understanding before you spend money.

Why does that activin piece matter so much? Because your body doesn't run this system the way a mouse does. In mice, myostatin is the dominant signal, but in humans and primates, active and A circulates at comparable levels to myostatin and actually binds to the same receptors with 20 times higher affinity.

Block myostatin alone in a human and activin A is still sitting on the same receptor, still driving the same suppression pathway, still doing about half the work of holding your muscle back.

The second modification is an albumin binding construct, a 29 amino acid addition designed to extend the half-life by attaching to albumin in your blood.

Albumin recycles through your system on roughly a 19 day cycle, and the idea is that FLGR242 hitches a ride on it instead of being cleared in hours.

That approach has already been validated elsewhere, since semaglutide uses the same trick and it works. But semaglutide is a 4 kDa peptide and FLGR242 is a 40 kDa protein, which is ten times the size, and size changes how a molecule distributes, how it clears, and how well albumin binding actually rescues it.

There is no published Cmax for FLGR242, no measured half-life in a human, and no dose response curve. The 19 day number is an inference from albumin's behavior, not a measurement of this molecule.

Jay Campbell is the primary person promoting the compound, and he is the co-founder and co-owner of BioLongevity Labs, which manufactures and sells it.

He previously published an article on his own website titled Stay Away from Pholestatin 344, where he specifically wrote that mouse myostatin models don't translate well to humans because mice have 3 to 10 times higher myostatin expression than we do, and he reversed that position once he developed FLGR242 himself.

His website cites 24 scientific references, and every single one is an animal study or a cell culture experiment. Not one of them studies FLGR242 in a human.

The patent covering the albumin binding technology is owned by an individual named Michael Farber, not by BioLongevity Labs, and no licensing arrangement has been publicly disclosed.

The industry history matters here too, because this has been attempted repeatedly with real budgets. Wyeth, Pfizer, Roche, Novartis and Acceleron all developed myostatin inhibitors, all of them reliably increased muscle volume on imaging, and all of them failed to produce meaningful improvements in strength or physical function.

So basically the industry has learned that blocking myostatin grows muscle that doesn't necessarily perform better, and every company in this space has now pivoted towards obesity and GLP-1 combination therapy instead.

If you take the bimagrumab analog data as the closest reference point, the honest ceiling for a myostatin-only approach layered on top of TRT is somewhere around one to three kilograms of additional lean mass over three to six months. That's the realistic number, and it's a long way from a pound and a half per week.

There's also a delivery problem that gets glossed over when people cite the gene therapy results as evidence for an injectable protein.

Gene therapy puts a virus inside your muscle cells and those cells manufacture follistatin locally and continuously for months, right where it needs to act. A subcutaneous injection of a 40 kDa protein has roughly 50 to 80 percent bioavailability, gets diluted across your entire body instead of concentrating in muscle tissue, and is subject to degradation along the way.

The dose math looks reasonable at peak, since five milligrams gets you to about 75 times your endogenous levels, but the mouse study that showed meaningful muscle gains required an allometric dose equivalent to about 360 milligrams in a human, and stability is a concern.

Published data shows 22 percent bioactivity loss within 72 hours at refrigerator temperature and 15 to 30 percent per freeze-thaw cycle, which means the potency in the vial depends heavily on how it was shipped, stored, and handled before it reached you.

The question that's left is what people who are actually injecting phallostatin are experiencing, and that data looks very different from the claims being made.

Forum logs going back more than a decade show the same pattern over and over, which is that most users report nothing happened.

The most dramatic report was a user who gained 17 pounds in three weeks from one batch that could never replicate it from any vendor, including the same one, which points at batch variability or contamination rather than a reproducible drug effect.

A published analytical study found that only 53 percent of black market follistatin products actually contained the protein at all, with the rest being unrelated peptides or nothing.

And every single user log involves stacking with testosterone, growth hormone, or anabolic steroids, so there is no clean data point anywhere isolating what follistatin alone does in a human.

Campbell's own eight-week run on FLGR242 showed roughly two pounds of weight change while running TRT, growth hormone, and other compounds simultaneously.

On safety, the cancer concern is specific rather than vague. The published literature suggests follistatin promotes the growth of tumors that already exist without appearing to initiate new ones.

That distinction matters because about 15 to 20 percent of men in their 40s carry occult tumors they don't know about, predominantly indolent prostate cancer, so if you're going to use any compound that could accelerate what's already there, comprehensive screening is worth considering.

Beyond cancer, myostatin-deficient animal models consistently show tendons that don't scale with muscle growth and cardiac changes that may not be protective long term, and cessation data from the closest mouse analog shows that gains fully reverse within about 145 days of stopping because myostatin inhibition grows muscle by expanding existing cell domains, not by adding new muscle nuclei the way resistance training does.

That last mechanism is the one people skip past, and it explains why training isn't optional with this pathway. Each muscle nucleus governs a fixed volume of muscle fiber, and myostatin inhibition stretches that governed volume larger without adding nuclei, so the moment the signal stops, the fiber shrinks back toward the size its existing nuclei can maintain.

Resistance training works through a different mechanism, recruiting satellite cells that donate new nuclei to the fiber and permanently raising the ceiling on how much tissue that fiber can hold.

You can see the difference in the trial data. In the inclusion body myositis gene therapy trial, patients who exercise gained 58 to 153 meters on their walking test, while patients on the same treatment who didn't exercise only gained 5 to 23 meters.

Same drug, same dose, same delivery, and the entire functional benefit landed on the people who trained.

Now as far as dosing is concerned, Jay Campbell himself recommends three dosing tiers, 5 milligrams every two weeks, two and a half milligrams weekly, or five to ten milligrams daily for advanced use. There is no human dose finding study behind any of those numbers, and the spread between the lowest and highest tier is roughly 28-fold, which tells you the protocols are estimates rather than findings.

So the pathway itself holds up, backed by human genetics, primate work, and the Nationwide Children's gene therapy trials all pointing the same direction, with billions of pharmaceutical dollars spent confirming that blocking this brake grows tissue.

Whether FLGR 242 specifically delivers on the claims being made about it is something that nobody can answer right now because the data just doesn't exist. No human pharmacokinetics, no controlled efficacy trial, no independent purity testing, no long-term safety follow-up.

When the strongest evidence for a compound is the developer's own eight-week log while he was also running testosterone and growth hormone, and his earlier writing already explained why the mouse data he now cites wouldn't translate to humans, the thing being sold isn't a result.

It's an experiment, and the price of the vial is the cost of volunteering to run it on yourself.

References:

Mendell JR, Sahenk Z, Al-Zaidy S et al.. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017. https://pubmed.ncbi.nlm.nih.gov/28279643/

Mendell JR, Rodino-Klapac L, Sahenk Z et al.. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett. 2012. https://pubmed.ncbi.nlm.nih.gov/22609847/